Researchers at the Scripps Research Institute have solved the structure of the Piezo1 protein, which is responsible for the sense of touch. Piezo1 converts physical stimuli like touch or blood flow into chemical signals. Understanding the structure of Piezo1 provides insight into how proteins sense mechanical force and which regions can be targeted with drugs. The findings shed light on the fundamental process of touch sensation and may help develop treatments for conditions caused by Piezo1 malfunctions.
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning.” — Steve Jobs
While analyzing the effects of radio frequency heating on hypothermia in the year 1941, Canadian electrical engineer John Hopps read that if the heart stops beating due to an acute drop in temperature, it could successfully be brought back to life artificially using mechanical or electrical stimulation.
The document discusses two scientific studies investigating methods to inhibit DNA replication:
1) A 2017 study found that the bacterial toxin yatakemycin prevents DNA replication by forming strong bonds between DNA strands. This could potentially treat cancers and illnesses.
2) A second 2017 study identified a new antibiotic, closthioamide, that shows promise in treating gonorrhea. It inhibits DNA gyrase to block replication in Neisseria gonorrhoeae bacteria. Both studies explore new approaches to targeting DNA replication that could expand treatment options.
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...Nora Piedad Velasquez
The scientists identified a novel compound that inhibits virus replication. Additionally, mutations in the reticulon 2 gene were found to cause hereditary spastic paraplegia, providing clues about axon degeneration. Identifying the specific mutated points allows for genetic testing and counseling while also furthering research into degenerative diseases.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Gene therapy is used to correct defective genes in order to cure a disease or help your body better fight disease. Researchers are investigating several ways to do this, including: Replacing mutated genes. Some cells become diseased because certain genes work incorrectly or no longer work at all.
Hiv aids sample questions based on neet pg , usmle, plab and fmge pattern (mc...Medico Apps
The document discusses HIV and the risk of infection from needle stick injuries. It notes that the chance of HIV infection from a needle stick injury is 1 in 300, or 0.3%. Prompt use of antiretroviral drugs as post-exposure prophylaxis can decrease this risk. Common symptoms during the asymptomatic latent phase of HIV infection include proliferation of the virus in follicular dendritic cells in lymph nodes. A Western blot test is highly specific for confirming the presence of HIV antibodies.
This document provides an introduction to transhumanism including definitions, goals, and an agenda covering various topics. It defines transhumanism as the belief that humans can evolve beyond limitations through science and technology. The agenda covers gene editing using CRISPR-Cas9, applications in diseases like sickle cell and blindness, brain-computer interfaces, anti-aging research, nanotechnology, and ethical issues. Experts discuss progress in areas like reversing age-related vision loss and potential for dramatically extending lifespan. Philosophical questions around human enhancement and what it means to be human are also raised.
This document discusses two scientific articles about cellular processes and potential applications to cancer treatment. The first article describes how a newly identified protease, Wss1, can chop down the protein components of DNA-protein crosslinks, allowing cells to replicate their genome. The second article discusses how DNA origami was used to test the effects of ephrin placement on the EphA2 receptor in cancer cells, finding it reduced invasiveness. The document concludes that further research using specialized techniques can improve understanding of disease pathophysiology and lead to potential cures in the future.
This document discusses new research that has developed a tool to analyze DNA and RNA strands much faster, in hours rather than months. Typically, specific DNA sequences were studied using melting curve analysis, but this method was found to be inaccurate. The new tool can more accurately measure thermodynamics at different temperatures and variables. It will make analysis available to more researchers. Faster DNA analysis could help further research on cell mutations and diseases, potentially leading to improved treatments by better understanding genetic and environmental factors involved in health conditions.
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning.” — Steve Jobs
While analyzing the effects of radio frequency heating on hypothermia in the year 1941, Canadian electrical engineer John Hopps read that if the heart stops beating due to an acute drop in temperature, it could successfully be brought back to life artificially using mechanical or electrical stimulation.
The document discusses two scientific studies investigating methods to inhibit DNA replication:
1) A 2017 study found that the bacterial toxin yatakemycin prevents DNA replication by forming strong bonds between DNA strands. This could potentially treat cancers and illnesses.
2) A second 2017 study identified a new antibiotic, closthioamide, that shows promise in treating gonorrhea. It inhibits DNA gyrase to block replication in Neisseria gonorrhoeae bacteria. Both studies explore new approaches to targeting DNA replication that could expand treatment options.
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...Nora Piedad Velasquez
The scientists identified a novel compound that inhibits virus replication. Additionally, mutations in the reticulon 2 gene were found to cause hereditary spastic paraplegia, providing clues about axon degeneration. Identifying the specific mutated points allows for genetic testing and counseling while also furthering research into degenerative diseases.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Gene therapy is used to correct defective genes in order to cure a disease or help your body better fight disease. Researchers are investigating several ways to do this, including: Replacing mutated genes. Some cells become diseased because certain genes work incorrectly or no longer work at all.
Hiv aids sample questions based on neet pg , usmle, plab and fmge pattern (mc...Medico Apps
The document discusses HIV and the risk of infection from needle stick injuries. It notes that the chance of HIV infection from a needle stick injury is 1 in 300, or 0.3%. Prompt use of antiretroviral drugs as post-exposure prophylaxis can decrease this risk. Common symptoms during the asymptomatic latent phase of HIV infection include proliferation of the virus in follicular dendritic cells in lymph nodes. A Western blot test is highly specific for confirming the presence of HIV antibodies.
This document provides an introduction to transhumanism including definitions, goals, and an agenda covering various topics. It defines transhumanism as the belief that humans can evolve beyond limitations through science and technology. The agenda covers gene editing using CRISPR-Cas9, applications in diseases like sickle cell and blindness, brain-computer interfaces, anti-aging research, nanotechnology, and ethical issues. Experts discuss progress in areas like reversing age-related vision loss and potential for dramatically extending lifespan. Philosophical questions around human enhancement and what it means to be human are also raised.
This document discusses two scientific articles about cellular processes and potential applications to cancer treatment. The first article describes how a newly identified protease, Wss1, can chop down the protein components of DNA-protein crosslinks, allowing cells to replicate their genome. The second article discusses how DNA origami was used to test the effects of ephrin placement on the EphA2 receptor in cancer cells, finding it reduced invasiveness. The document concludes that further research using specialized techniques can improve understanding of disease pathophysiology and lead to potential cures in the future.
This document discusses new research that has developed a tool to analyze DNA and RNA strands much faster, in hours rather than months. Typically, specific DNA sequences were studied using melting curve analysis, but this method was found to be inaccurate. The new tool can more accurately measure thermodynamics at different temperatures and variables. It will make analysis available to more researchers. Faster DNA analysis could help further research on cell mutations and diseases, potentially leading to improved treatments by better understanding genetic and environmental factors involved in health conditions.
The documents discuss new research challenging the idea of the selfish gene, proposing that evolution is instead driven by the selfish ribosome. The ribosome contains the machinery for translating genetic information from DNA into proteins. Research suggests the ribosome was central to the origin of the first cell and its complex structure makes even minor mutations highly lethal for viruses. Studies of the central dogma of genetics and how life began are important for advancing medicine by providing new perspectives to approach genetic problems and find cures for diseases.
Nicholas Christopoulos provides a scientific skills profile and work history in his resume. He has 6 years of experience working in academic and medical labs conducting research in biology and chemistry. His skills include basic lab safety, culturing bacteria, working with zebrafish, using CRISPR, and organic synthesis. He has a B.S. in Biology and Chemistry from Guilford College with a 3.32 GPA and has presented research papers at several conferences. He interned with Dr. Mary Hutson at Duke Medical Center studying heart development in zebrafish embryos.
Break through in biochemistry biotechnology[616]Dr.K Madhuri
The document discusses recent breakthroughs in biotechnology, biochemistry, and biology. Some key points include:
- Researchers have developed a device called the Moosy 32 eNose that can detect colon diseases by analyzing volatile compounds.
- Scientists have created human-pig embryos and developed an artificial womb to help extremely premature lambs survive.
- A new method called "cellular leapfrogging" allows mature cells like liver cells to be transformed into other cell types like neurons.
- CAR T-cell immunotherapy was approved for cancer treatment, engineering immune cells to target tumors.
- Advances could help address problems like malnutrition, crop failure, and extend human lifespans.
This document is a resume for Sandra Anderson LaSalle, who has over 20 years of experience in clinical and basic science research. She has worked in a variety of roles including as a research scientist at Merck, Pfizer, and various universities. Her experience includes laboratory management, product development, clinical research, and teaching. She has advanced knowledge in microbiology and experience in fields like oncology, diabetes, and female reproduction.
The Genomics Revolution: The Good, The Bad, and The Ugly (UEOP16 Keynote)Emiliano De Cristofaro
The document discusses the genomics revolution and its implications for privacy. It outlines the good of genetic testing and medicine, the bad of collecting sensitive genomic data that is hard to anonymize, and the ugly challenges of balancing privacy and the greater good. It then reviews the history of genome sequencing and cost reductions. The remainder summarizes privacy issues like re-identification risks, kin privacy, and challenges of data sharing. It also outlines cryptography techniques being explored to enable private genomic computation and testing on encrypted genomes. Open problems remain around long-term data storage and usability of privacy techniques.
Severe combined immunodeficiency (SCID), also known as "bubble boy disease", is a genetic disorder where both the B cell and T cell arms of the immune system are impaired. SCID results in an almost entirely absent immune system, leaving affected children highly vulnerable to life-threatening infections from a very young age. The standard treatment is a bone marrow transplant from a matched or partially matched donor to rebuild the immune system. Gene therapy is also being studied as a potential treatment but remains experimental. Without treatment, SCID is typically fatal in early childhood.
This document discusses using a knowledge graph and machine learning techniques to generate hypotheses for clinical therapies for NGLY1 deficiency, a rare genetic disease. It describes biocuration efforts to capture the pathophysiology and phenotypic spectrum of NGLY1 deficiency and add this information to a knowledge graph. The document proposes using the updated knowledge graph with an edge prediction algorithm called Rephetio to identify potential drug repurposing candidates for treating NGLY1 deficiency.
El programa INPhINIT está dirigido a los candidatos de doctorado más motivados y se centra en los campos de investigación en los que España destaca: las ciencias de la salud y de la vida, la tecnología, la física, la ingeniería y las matemáticas https://obrasociallacaixa.org/es/educacion-becas/becas-de-posgrado/inphinit/programme-description
This study evaluated the use of gentamicin microspheres to locally deliver antibiotics and reduce postoperative spinal implant infections in rabbits. In the first phase, various bacterial doses were tested in rabbits to determine a dose that resulted in a 70% surgical site infection rate. This established dose (106 CFU of Staphylococcus aureus) was then used in the second phase where sites received either gentamicin microspheres or a control treatment. Results showed that the gentamicin microspheres significantly reduced both the surgical site infection rate and implant-associated infection rate compared to the control sites. Bacterial counts were also lower in infected sites that received the gentamicin treatment, though this difference was not statistically significant. This suggests
EXHIBIT A
V A C C I N E - A N A L Y S I S - B Y - D R . R O B E R T - Y O U NG
Graphene Oxide; also known as G.O. is a compound of magnetic nanoparticles.
This document summarizes research on the use of adeno-associated virus (AAV) as a vector for gene therapy. AAV is a promising delivery method due to its low immunogenicity, ability to target specific cell types, and lack of pathogenicity. The document discusses how AAV is being used experimentally to treat diseases like cystic fibrosis, cancer, and heart disease by delivering therapeutic genes. While challenges remain, AAV vectors appear safer than other methods and have the potential to treat many currently incurable diseases.
Determination and comparison rate of expression markers of osteoblast derived...IJERD Editor
Nowadays high accident rates, fractures leading to permanent bone disorders and the impossibility of bone transplant have made scientists to look for new methods of repairing injured bones. Considering the application of stem cells in bone tissue engineering, there exists the necessity to investigate various culture methods and suitable fields and scaffolds. Thus, we decided to induce adipose-derived stem cells into osteoblast cells in two systems of pellet culture and monolayer and compare osteogenic markers. Methods: Stem cells have been separated via mechanical and enzymatic methods and cultured in monolayer and pellet culture models with osteogenic medium. Then, RNA was separated from differentiated cells, complementary DNA (cDNA) was synthesized and amplified. Polymerase chain reaction (PCR) product was transferred to electrophoresis gel. The intensity of the bands was measured by Image-J software and analyzed by SPSS.
This document discusses next generation sequencing to identify bacteria, fungi, and viruses from patient samples. It summarizes discussions and presentations from several ear, nose, and throat doctors and researchers on using DNA sequencing to diagnose biofilm infections. DNA sequencing was able to identify more pathogens than traditional cultures and provided faster results. Identifying biofilms is important as they are resistant to antibiotics and cause chronic infections. The document promotes using a molecular diagnostic test from PathoGenius to identify pathogens in patient samples, which it says provides faster, more comprehensive results than cultures and is covered by Medicare.
The document summarizes recent publications from The Journal of Experimental Medicine focusing on neuroscience. It highlights several studies: one finding that monocyte-derived macrophages initiate myelin destruction in multiple sclerosis, while microglia-derived macrophages clear debris; another activating B-RAF kinase to promote axon regeneration after nerve injury; and one showing that blocking interleukin-21 reduces brain injury following stroke in mice. It also summarizes studies on retinal thinning in frontotemporal dementia and targeting neurovascular pathology in Alzheimer's disease models.
1. Whole genome sequencing is becoming more affordable and widespread, allowing for large datasets and personalized medicine applications.
2. However, genomic data is extremely sensitive and can be used to identify individuals and their relatives, even when anonymized. Once a genome is leaked, it cannot be revoked.
3. Computer scientists are exploring techniques to protect genomic privacy, such as differential privacy and secure computation, but enabling privacy-preserving genomic research remains a challenge.
Medical Biotechnology and Genetics Journal - SciDocPublishersScidoc Publishers
International Journal of Medical Biotechnology & Genetics (IJMBG) ISSN: 2379-1020 is a comprehensive, peer reviewed journal devoted to Medical Biotechnology & Genetics. IJMBG, published by SciDocPublishers is an Open Access journal that includes high quality papers, which covers all major areas of Medical Biotechnology & Genetics. SciDocPublishers with its Open Access publication model spreads all the day-to-day developments and research to readers around the world.
IJMBG retains its interest in evolutionary research as an international journal dedicated to the latest advancement of Medical Biotechnology & Genetics. It provides a platform for Scientists and Academicians all over the world to promote, share, and discuss various new issues and developments in different areas of Medical Biotechnology & Genetics.
For more details: http://scidoc.org/medical-biotechnology-and-genetics.php
Next-generation sequencing is providing new insights into inherited retinal dystrophies. The following key points are made:
1) Current molecular diagnosis can identify the disease mechanism in 50-60% of nonsyndromic retinal dystrophy patients. Multiple pathogenic variants may be present.
2) Analysis of the ABCA4 gene, associated with Stargardt disease, has uncovered deep intronic mutations and rare combinations of mutations in multiple genes.
3) Interpretation of sequencing results is challenging due to the discovery of variants of uncertain significance and complications with inheritance patterns. Retinal dystrophy is becoming a model for studying the molecular basis of rare genetic diseases.
This document discusses recent discoveries of transgenic hydra and parasites found in COVID vaccines. It claims that hydra and parasites have been genetically modified and are being used as part of a "vaccine operating system" to rewrite human genes, build an artificial neural network, and rapidly clone humans. The document outlines scientific studies it says were used to develop this system using techniques like CRISPR, mRNA, graphene oxide, and luciferase to track and control gene expression in vaccinated individuals.
This document summarizes two scientific articles. The first article describes a new method called PIP-seq that establishes a complete footprint of RNA-protein interactions by comparing protein-bound RNA segments protected from degradation to a control sample. The second article describes a novel approach using the single-celled fungus saccharomyces cerevisiae to understand how individual genetic variants affect gene expression over a two-and-a-half year study period. The observation notes that choosing a simple organism provides insights into RNA expression, genetic variations, and protein regulation applicable to human genetics, with implications for precision medicine through understanding disease vulnerability and tailoring treatments.
Christopher Korch has identified hundreds of widely used cell lines that are contaminated with other cell types. He estimates that around 20% of cell lines are contaminated. Korch has quantified the impact of two contaminated cell lines, HEp-2 and INT-407, which are actually composed of cancerous HeLa cells but have been used to study other tissue types. HEp-2 has been used in over 5,700 publications referring to laryngeal cancer, while INT-407 has been used in over 1,300 publications referring to normal intestine. Korch estimates the total citations influenced by these misidentified lines could be over 200,000. The estimated costs of the original research on these lines is $713 million, with an
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...Nora Piedad Velasquez
1) A team of scientists identified a novel compound that inhibits viruses from replicating, which could lead to new drugs to block poxviruses like monkeypox.
2) Mutations in the reticulon 2 gene were found to cause a form of hereditary spastic paraplegia by disrupting endoplasmic reticulum shaping and causing axon degeneration.
3) Identifying the specific location of genetic mutations, such as deletions in chromosomes, allows for a better understanding of disease incidence and development, aiding in potential prevention and treatment.
This document discusses several topics related to genetics and cloning. It defines different types of genetic inheritance including dominant/recessive alleles and co-dominant alleles. It then discusses the human genome project, genetic disorders like single gene disorders and chromosome abnormalities, and recent advancements in organ cloning including creating a urethra and reducing rejection risks. It argues the benefits of organ cloning and concludes by discussing the potential for engineering replacement organs.
The documents discuss new research challenging the idea of the selfish gene, proposing that evolution is instead driven by the selfish ribosome. The ribosome contains the machinery for translating genetic information from DNA into proteins. Research suggests the ribosome was central to the origin of the first cell and its complex structure makes even minor mutations highly lethal for viruses. Studies of the central dogma of genetics and how life began are important for advancing medicine by providing new perspectives to approach genetic problems and find cures for diseases.
Nicholas Christopoulos provides a scientific skills profile and work history in his resume. He has 6 years of experience working in academic and medical labs conducting research in biology and chemistry. His skills include basic lab safety, culturing bacteria, working with zebrafish, using CRISPR, and organic synthesis. He has a B.S. in Biology and Chemistry from Guilford College with a 3.32 GPA and has presented research papers at several conferences. He interned with Dr. Mary Hutson at Duke Medical Center studying heart development in zebrafish embryos.
Break through in biochemistry biotechnology[616]Dr.K Madhuri
The document discusses recent breakthroughs in biotechnology, biochemistry, and biology. Some key points include:
- Researchers have developed a device called the Moosy 32 eNose that can detect colon diseases by analyzing volatile compounds.
- Scientists have created human-pig embryos and developed an artificial womb to help extremely premature lambs survive.
- A new method called "cellular leapfrogging" allows mature cells like liver cells to be transformed into other cell types like neurons.
- CAR T-cell immunotherapy was approved for cancer treatment, engineering immune cells to target tumors.
- Advances could help address problems like malnutrition, crop failure, and extend human lifespans.
This document is a resume for Sandra Anderson LaSalle, who has over 20 years of experience in clinical and basic science research. She has worked in a variety of roles including as a research scientist at Merck, Pfizer, and various universities. Her experience includes laboratory management, product development, clinical research, and teaching. She has advanced knowledge in microbiology and experience in fields like oncology, diabetes, and female reproduction.
The Genomics Revolution: The Good, The Bad, and The Ugly (UEOP16 Keynote)Emiliano De Cristofaro
The document discusses the genomics revolution and its implications for privacy. It outlines the good of genetic testing and medicine, the bad of collecting sensitive genomic data that is hard to anonymize, and the ugly challenges of balancing privacy and the greater good. It then reviews the history of genome sequencing and cost reductions. The remainder summarizes privacy issues like re-identification risks, kin privacy, and challenges of data sharing. It also outlines cryptography techniques being explored to enable private genomic computation and testing on encrypted genomes. Open problems remain around long-term data storage and usability of privacy techniques.
Severe combined immunodeficiency (SCID), also known as "bubble boy disease", is a genetic disorder where both the B cell and T cell arms of the immune system are impaired. SCID results in an almost entirely absent immune system, leaving affected children highly vulnerable to life-threatening infections from a very young age. The standard treatment is a bone marrow transplant from a matched or partially matched donor to rebuild the immune system. Gene therapy is also being studied as a potential treatment but remains experimental. Without treatment, SCID is typically fatal in early childhood.
This document discusses using a knowledge graph and machine learning techniques to generate hypotheses for clinical therapies for NGLY1 deficiency, a rare genetic disease. It describes biocuration efforts to capture the pathophysiology and phenotypic spectrum of NGLY1 deficiency and add this information to a knowledge graph. The document proposes using the updated knowledge graph with an edge prediction algorithm called Rephetio to identify potential drug repurposing candidates for treating NGLY1 deficiency.
El programa INPhINIT está dirigido a los candidatos de doctorado más motivados y se centra en los campos de investigación en los que España destaca: las ciencias de la salud y de la vida, la tecnología, la física, la ingeniería y las matemáticas https://obrasociallacaixa.org/es/educacion-becas/becas-de-posgrado/inphinit/programme-description
This study evaluated the use of gentamicin microspheres to locally deliver antibiotics and reduce postoperative spinal implant infections in rabbits. In the first phase, various bacterial doses were tested in rabbits to determine a dose that resulted in a 70% surgical site infection rate. This established dose (106 CFU of Staphylococcus aureus) was then used in the second phase where sites received either gentamicin microspheres or a control treatment. Results showed that the gentamicin microspheres significantly reduced both the surgical site infection rate and implant-associated infection rate compared to the control sites. Bacterial counts were also lower in infected sites that received the gentamicin treatment, though this difference was not statistically significant. This suggests
EXHIBIT A
V A C C I N E - A N A L Y S I S - B Y - D R . R O B E R T - Y O U NG
Graphene Oxide; also known as G.O. is a compound of magnetic nanoparticles.
This document summarizes research on the use of adeno-associated virus (AAV) as a vector for gene therapy. AAV is a promising delivery method due to its low immunogenicity, ability to target specific cell types, and lack of pathogenicity. The document discusses how AAV is being used experimentally to treat diseases like cystic fibrosis, cancer, and heart disease by delivering therapeutic genes. While challenges remain, AAV vectors appear safer than other methods and have the potential to treat many currently incurable diseases.
Determination and comparison rate of expression markers of osteoblast derived...IJERD Editor
Nowadays high accident rates, fractures leading to permanent bone disorders and the impossibility of bone transplant have made scientists to look for new methods of repairing injured bones. Considering the application of stem cells in bone tissue engineering, there exists the necessity to investigate various culture methods and suitable fields and scaffolds. Thus, we decided to induce adipose-derived stem cells into osteoblast cells in two systems of pellet culture and monolayer and compare osteogenic markers. Methods: Stem cells have been separated via mechanical and enzymatic methods and cultured in monolayer and pellet culture models with osteogenic medium. Then, RNA was separated from differentiated cells, complementary DNA (cDNA) was synthesized and amplified. Polymerase chain reaction (PCR) product was transferred to electrophoresis gel. The intensity of the bands was measured by Image-J software and analyzed by SPSS.
This document discusses next generation sequencing to identify bacteria, fungi, and viruses from patient samples. It summarizes discussions and presentations from several ear, nose, and throat doctors and researchers on using DNA sequencing to diagnose biofilm infections. DNA sequencing was able to identify more pathogens than traditional cultures and provided faster results. Identifying biofilms is important as they are resistant to antibiotics and cause chronic infections. The document promotes using a molecular diagnostic test from PathoGenius to identify pathogens in patient samples, which it says provides faster, more comprehensive results than cultures and is covered by Medicare.
The document summarizes recent publications from The Journal of Experimental Medicine focusing on neuroscience. It highlights several studies: one finding that monocyte-derived macrophages initiate myelin destruction in multiple sclerosis, while microglia-derived macrophages clear debris; another activating B-RAF kinase to promote axon regeneration after nerve injury; and one showing that blocking interleukin-21 reduces brain injury following stroke in mice. It also summarizes studies on retinal thinning in frontotemporal dementia and targeting neurovascular pathology in Alzheimer's disease models.
1. Whole genome sequencing is becoming more affordable and widespread, allowing for large datasets and personalized medicine applications.
2. However, genomic data is extremely sensitive and can be used to identify individuals and their relatives, even when anonymized. Once a genome is leaked, it cannot be revoked.
3. Computer scientists are exploring techniques to protect genomic privacy, such as differential privacy and secure computation, but enabling privacy-preserving genomic research remains a challenge.
Medical Biotechnology and Genetics Journal - SciDocPublishersScidoc Publishers
International Journal of Medical Biotechnology & Genetics (IJMBG) ISSN: 2379-1020 is a comprehensive, peer reviewed journal devoted to Medical Biotechnology & Genetics. IJMBG, published by SciDocPublishers is an Open Access journal that includes high quality papers, which covers all major areas of Medical Biotechnology & Genetics. SciDocPublishers with its Open Access publication model spreads all the day-to-day developments and research to readers around the world.
IJMBG retains its interest in evolutionary research as an international journal dedicated to the latest advancement of Medical Biotechnology & Genetics. It provides a platform for Scientists and Academicians all over the world to promote, share, and discuss various new issues and developments in different areas of Medical Biotechnology & Genetics.
For more details: http://scidoc.org/medical-biotechnology-and-genetics.php
Next-generation sequencing is providing new insights into inherited retinal dystrophies. The following key points are made:
1) Current molecular diagnosis can identify the disease mechanism in 50-60% of nonsyndromic retinal dystrophy patients. Multiple pathogenic variants may be present.
2) Analysis of the ABCA4 gene, associated with Stargardt disease, has uncovered deep intronic mutations and rare combinations of mutations in multiple genes.
3) Interpretation of sequencing results is challenging due to the discovery of variants of uncertain significance and complications with inheritance patterns. Retinal dystrophy is becoming a model for studying the molecular basis of rare genetic diseases.
This document discusses recent discoveries of transgenic hydra and parasites found in COVID vaccines. It claims that hydra and parasites have been genetically modified and are being used as part of a "vaccine operating system" to rewrite human genes, build an artificial neural network, and rapidly clone humans. The document outlines scientific studies it says were used to develop this system using techniques like CRISPR, mRNA, graphene oxide, and luciferase to track and control gene expression in vaccinated individuals.
This document summarizes two scientific articles. The first article describes a new method called PIP-seq that establishes a complete footprint of RNA-protein interactions by comparing protein-bound RNA segments protected from degradation to a control sample. The second article describes a novel approach using the single-celled fungus saccharomyces cerevisiae to understand how individual genetic variants affect gene expression over a two-and-a-half year study period. The observation notes that choosing a simple organism provides insights into RNA expression, genetic variations, and protein regulation applicable to human genetics, with implications for precision medicine through understanding disease vulnerability and tailoring treatments.
Christopher Korch has identified hundreds of widely used cell lines that are contaminated with other cell types. He estimates that around 20% of cell lines are contaminated. Korch has quantified the impact of two contaminated cell lines, HEp-2 and INT-407, which are actually composed of cancerous HeLa cells but have been used to study other tissue types. HEp-2 has been used in over 5,700 publications referring to laryngeal cancer, while INT-407 has been used in over 1,300 publications referring to normal intestine. Korch estimates the total citations influenced by these misidentified lines could be over 200,000. The estimated costs of the original research on these lines is $713 million, with an
Novel Compound to Halt Virus replication Identified AND Spasticity Gene Findi...Nora Piedad Velasquez
1) A team of scientists identified a novel compound that inhibits viruses from replicating, which could lead to new drugs to block poxviruses like monkeypox.
2) Mutations in the reticulon 2 gene were found to cause a form of hereditary spastic paraplegia by disrupting endoplasmic reticulum shaping and causing axon degeneration.
3) Identifying the specific location of genetic mutations, such as deletions in chromosomes, allows for a better understanding of disease incidence and development, aiding in potential prevention and treatment.
This document discusses several topics related to genetics and cloning. It defines different types of genetic inheritance including dominant/recessive alleles and co-dominant alleles. It then discusses the human genome project, genetic disorders like single gene disorders and chromosome abnormalities, and recent advancements in organ cloning including creating a urethra and reducing rejection risks. It argues the benefits of organ cloning and concludes by discussing the potential for engineering replacement organs.
This document discusses several topics related to genetics and cloning, including:
- Different types of genetic inheritance like dominant, recessive, and codominant alleles
- The goals and implications of the Human Genome Project
- Different types of genetic disorders like single gene disorders, chromosome abnormalities, and multifactorial disorders
- Scientific advancements in organ cloning research, including creating tissues and organs using cells and scaffolds
- Arguments for and against organ cloning, and potential future applications of this research
This document discusses several topics related to genetics and cloning. It defines different types of genetic inheritance including dominant, recessive, and co-dominant alleles. It also describes genetic disorders such as single gene disorders, chromosome abnormalities, and multifactorial disorders. Additionally, it discusses recent scientific advancements in organ cloning and regeneration at the Wake Forest Institute for Regenerative Medicine.
This document discusses several topics related to genetics and cloning. It defines different types of genetic inheritance including dominant, recessive, and co-dominant alleles. It also describes genetic disorders such as single gene disorders, chromosome abnormalities, and multifactorial disorders. Additionally, it discusses recent scientific advancements in organ cloning and regeneration at the Wake Forest Institute for Regenerative Medicine.
Biology, genetics, nanotechnology, neuroscience, materials science, biotech, ...Brian Russell
Over the past two years I've done a lot of interesting research which I've decided to aggregate. My research pertains to the following: Biology, Genetics, Nanotechnology, Neuroscience, Materials Science, Biotechnology, Chemical Engineering, All Things 3-D, Super Computing, Quantum Physics, Energy, Design, & Sustainability.
Eukaryotic cells have their genetic material in the nucleus, in the other side, prokaryotes have it dispersed in the cytoplasm.
From this DNA will be synthesized RNA, which will act as an intermediary, carrying genetic information from the nucleus to the ribosomes located in the cytoplasm to carry out protein synthesis.
genetic code consists of 64 triplets (codons) of nucleotides, each codon encodes for one of the 20 amino-acids used in the synthesis of proteins.
The study of the genetic code, allow s us identify mutations in specific genes, to detect diseases or predispositions to some pathologies such as those proposed by the articles, and with tan information, implement a PREVENTIVE MEDICINE.
Knowing the sequence of genes that cause certain genetic diseases, is essential for GENE THERAPY branch. In brief it consist in introduce a correct copy of the defective gene that was visualized into the cells, by some vectors, previously studied.
With the knowledge of genetic information, can be provided counseling before and after pregnancy to future parents (Give information about the diseases to which it is susceptible and existing treatments), having always instilled an ethical principle: THE HUMAN LIFE RESPECT.
Promote investigation in medicine basic areas, such as cell biology, molecular biology, biochemistry and pharmacology, with the aim of implement humanity solutions .
This document provides an introduction to biotechnology. It defines biotechnology as the use of living cells, including microorganisms, plant cells, and animal cells, for the benefit of humanity. Key areas of biotechnology discussed include agriculture, food, industry, biofuels, cosmetics, pharmaceuticals, and waste utilization. The document outlines several important techniques in biotechnology such as genetic engineering, gene therapy, bioinformatics, restriction enzymes, reverse transcriptase, polymerase chain reaction, genetic fingerprinting, cloning, and genetically modified plants.
Cloning extinct animals could help preserve genetic diversity and assist conservation efforts. Frozen zoos store genetic material from endangered species that could be used for cloning or artificial reproduction in the future. While damaged DNA may prevent cloned embryos from developing, repositories of frozen tissue aim to establish a "genetic trust fund" for reconstituting extinct populations. Advanced Cell Technology has successfully cloned an endangered animal, demonstrating cloning's potential for aiding species preservation.
This document summarizes key findings in the new field of epigenetics. It discusses how environmental factors like diet and stress can induce epigenetic changes that alter gene expression without changing DNA. Specifically, it describes an experiment where changing mother mice's diet resulted in offspring with different physical traits and disease risks. The document also discusses how epigenetic changes can be passed down generations, how the human epigenome is as important as DNA, links between epigenetics and diseases like cancer, and how nurturing behaviors in rats can induce epigenetic changes in offspring's brains that affect stress responses.
Genetic counselors help people understand their risk of inheriting genetic disorders. They take family medical histories and may order tests like karyotyping, which examines chromosomes to identify abnormalities that could cause genetic diseases. While some argue cloning could help preserve endangered and extinct species by maintaining their genetic diversity, others have ethical concerns about the technique. Scientists have made progress with cross-species cloning, successfully cloning an endangered animal late into fetal development using cow eggs, representing an important step.
RECOMBINANT DNA TECHNOLOGY AND ITS APPLICATIONStanz Ng
Recombinant DNA technology has had widespread global impacts. It has applications in medicine like producing insulin, vaccines, and cancer treatments. In agriculture, it has led to herbicide and insect resistant crops as well as efforts to engineer nitrogen-fixing plants. It also has uses in animal husbandry such as producing transgenic animals. Additional applications include DNA fingerprinting for forensics, producing monoclonal antibodies, and developing diagnostic tests and gene therapies. While offering benefits, it also raises ethical issues that require ongoing research and regulation.
The document summarizes several studies on DNA replication and the molecular machinery involved. It describes how researchers used tools like molecular biology and biochemistry to slow down and "freeze" the replication process at intermediate steps. This allowed them to observe conformational changes in proteins like the origin recognition complex (ORC) as it recruits the helicase enzyme to unwind DNA. Cryo-electron microscopy was then used to capture 3D structures of the protein components and reveal how they interact during replication initiation. The studies provide new insights into this critical cellular process.
The document discusses the importance of DNA replication for life and medicine. DNA replication is essential for cell division and is targeted by chemotherapy drugs to stop the growth of cancer cells. Understanding DNA replication better through research could help develop preventative treatments for diseases and improve medical knowledge.
Genetic engineering involves modifying an organism's genes using technology. It was first achieved in 1973 when Herbert Boyer and Stanley Cohen inserted antibiotic resistance genes into bacterial DNA. Rudolf Jaenisch then created the first genetically modified animal, a mouse, in 1974. In 1994, the first genetically modified food, a longer-lasting tomato, was approved for sale. More recently, scientists have developed new gene editing tools like CRISPR that allow more precise genetic modifications. While genetic engineering enables benefits like increased food production and disease resistance, it also raises concerns about unintended health and environmental impacts.
Promise Seen in Antisense Medicine and Neutralizing Harmful GenesGatewayAvenue
By Marilyn Chase
Illustration by Michael Reingold
August 22, 1988
Article includes, in order mentioned:
Thomas Rogers, Monsanto scientist
Michael L Riordan, the founder and CEO of Gilead Sciences
Samuel Broder, National Cancer Institute associate director
Claude Helene, scientist at France’s National Institute for Health and Medical Research
Paul Miller, Johns Hopkins professor
Laure Aurelian, University of Maryland professor
Jack Cohen, National Cancer Institute scientist
Makoto Matsukura, National Cancer Institute scientist
Len Neckers, National Cancer Institute scientist
Peter Dervan, California Institute of Technology professor
Douglas Melton, Harvard professor
Hal Weintraub, Hutchinson Cancer Research Center principal scientist
1) The document discusses the potential uses and benefits of stem cell research, including curing diseases like Alzheimer's, blood disorders, and birth defects.
2) It argues that stem cells can be used to generate organs and tissues to treat diseases. Stem cells may also reverse neural birth defects.
3) The conclusion is that the government should fund stem cell research because it could help cure many diseases and reduce waiting times for organ transplants. Researchers have also found ways to obtain stem cells without using embryos.
1) The document discusses how stem cells can potentially cure or treat various diseases and medical conditions like Alzheimer's, blood disorders, birth defects, and help generate organs.
2) It provides arguments for how stem cells have reversed neural defects in mice and could do the same for humans, in addition to being used to generate blood, bone marrow, heart, kidney, liver and lung cells/tissues.
3) The conclusion is that the government should fund stem cell research as it could find cures for diseases and reduce wait times for organ transplants, and stem cells don't need to come from embryos.
The document discusses two studies related to cells and medical applications. The first study investigated how bacteria can modify their cell walls to become resistant to antibiotics by changing peptidoglycan structure. The second study discusses the development of programmable RNA vaccines that can be rapidly produced in nanomaterials to provide protection against diseases like Ebola and influenza within days. Both studies demonstrate the importance of continued biological research on cells to develop new treatment methods and address issues like antimicrobial resistance and pandemic outbreaks.
Similar to Biotecnika Times newspaper Dated 1st Jan 2018 (20)
This document advertises the ARM Scholarship program which aims to equip students with guidance, training, and opportunities to pursue careers in research sciences. The program offers mentorship from over 120 experts, hands-on lab training, internships, entrance exam coaching, workshops, and conferences. It provides personalized attention, learning tools, and mock tests to help students prepare for exams like CSIR NET. The goal is to empower students and lower barriers like costs, lack of guidance and experience that currently prevent many from becoming scientists.
This document describes a scholarship program for CSIR NET exam preparation. It discusses strategies for exam preparation that involve building conceptual foundations and practicing concepts through various tools. It outlines the course structure which includes RAID classes in all sections taught by experienced faculty, personalized attention, animation tools for concepts, revision tools, and smart mock tests. Additional benefits include internship opportunities, workshops, career counseling, and a guarantee to repeat the course if the exam is postponed. The goal is to equip and empower students to win the CSIR NET exam in 2023 with the lowest possible fees.
This document summarizes an event for launching the Pratigya Batch for CSIR NET exam preparation. It outlines the agenda which includes discussions on vision and mission, myths vs facts, features students will get, where they can access materials, what is needed for preparation, and "magic potion" booster classes. Key facts are that students can qualify in 6 months with self-study and teacher support, only attending classes is not enough, and materials will be provided through an online study portal and workshops. The next CSIR NET exams will be in April and September 2023.
Microsoft, Apple, Amazon, and Alphabet are expanding into the pharmaceutical industry. Microsoft is creating healthcare software-as-a-service solutions and using artificial intelligence to help discover new drugs. Apple is collecting health data through devices like the Apple Watch and partnering with pharmaceutical companies to identify new digital biomarkers. Amazon aims to disrupt the pharmacy industry through its digital platform and supply chain expertise. Alphabet is using artificial intelligence and collected patient data to build new drug discovery capabilities internally.
Crack CSIR UGC NET chemical science - Study Planshekhar suman
Here are few tips on How you can Crack CSIR UGC NET chemical science in first attempt. Study plan for CSIR UGC NET chemical science has been discussed.
- Oral insulin capsules developed by Oramed Pharmaceuticals were found to successfully lower blood sugar levels in human clinical trials. The company is now conducting a larger 90-day study to further evaluate the capsules' effects on HbA1c and their potential as a safer, more convenient alternative to injected insulin.
- Scientists at the John Innes Centre identified the last missing genes in the Madagascar periwinkle plant that allow it to produce the important cancer-fighting alkaloids vinblastine and vincristine. Understanding these genes could help increase sustainable production of these drugs through plant or synthetic biology techniques.
- Researchers at multiple institutions reported developments that could help advance cancer treatment, including
Researchers at various institutions have made several advances:
1) IIT Roorkee researchers identified a molecule that shows 99% reduction of the chikungunya virus in lab tests, offering a potential new treatment.
2) Scientists at Maastricht University created an artificial embryo from stem cells that implanted in mice uteruses similarly to natural embryos, advancing understanding of embryonic development.
3) University of Toronto researchers developed a handheld 3D skin printer that could rapidly print skin grafts to treat deep wounds, aiming for future clinical trials and revolutionizing burn care.
How to Handle CSIR NET / GATE Exam Stress?shekhar suman
This document provides 15 tips for managing exam stress. The key tips include planning your study schedule, scheduling time for different subjects each day, taking disciplined action to stick to your schedule, using various techniques to improve concentration like deep breathing and mind maps, doing difficult subjects first, avoiding distractions, getting enough rest, unwinding yourself periodically, focusing on healthy food, and maintaining a positive attitude. Exam stress stems from pressures like expectations of good marks from parents, competitiveness, and fear of failure or rejection. Proper planning and time management along with stress-relieving activities can help deal with exam pressure effectively.
Biotecnika is India's Largest BioSciences Portal visited by 1 Million Biotech enthusiasts every month. Subscribe to our newsletter to stay updated about latest in the biotech industry
Rita Colwell has been awarded the prestigious International Prize for Biology 2017 for her outstanding contributions to marine microbiology, bioinformatics, microbiomes and understanding cholera. She helped show cholera is caused by environmental bacteria and associated with natural bacteria in zooplankton, not just person-to-person transmission. The prize recognizes her life-saving work on cholera prevention. Biotech startup Lumen has raised $13 million to develop its spirulina-based platform for producing natural colorants and biologics like drugs and vaccines. Its first product is a natural blue colorant for foods and cosmetics. The funds will support commercializing the colorant and developing the technology to produce additional colors and biolog
Living microbes have been documented for the first time in polar snow and ice samples. A new study analyzed snow samples from the University of York and found evidence of living bacteria in snowpacks through the presence of methyl iodide, a gas produced by marine bacteria. This challenges the assumption that polar ice cores are sterile and indicates that bacterial activity could be altering gas levels trapped in ice over millennia. The discovery suggests life may exist in other extreme icy environments and that ice core samples may need reevaluation to account for potential microbial impacts on trapped atmospheric gases.
Biotecnika Times Newspaper 13-February_2018shekhar suman
The FDA has approved the expanded use of the antibiotic Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by several gram-negative bacteria in patients 18 and older. This is the first new antibiotic approved to treat these infections caused by gram-negative bacteria in over 15 years. Studies showed Avycaz was as effective as other antibiotics and had a higher cure rate than best available treatment for these serious infections associated with critically ill hospitalized patients. The approval provides a new option for treating highly resistant gram-negative infections in the hospital setting.
This newspaper article summarizes various topics related to biotechnology careers and education in India. It discusses how India will need 2 million skilled biotech workers by 2020 to support the growing biopharma industry. It highlights the gap between the skills taught in university programs and the skills needed by industry. It provides tips on how to prepare for exams like CSIR NET and GATE to become a more competitive job applicant. One article profiles a woman who realized she needed to further her qualifications with a CSIR NET exam and additional certification to advance her career. Throughout, it emphasizes the growing opportunities and investments being made in the biotech sector in India.
Biotecnika Times Newspaper 6th December 2018shekhar suman
This summary provides the key details from the multi-page document in 3 sentences:
The document reports on recent scientific studies, including the development of a new type of biological data recorder using genetically modified E. coli bacteria. It also describes new "kill switch" mechanisms engineered into bacteria to ensure they self-destruct under certain conditions. Additionally, the document summarizes a study that found the process of clearing dying cancer cells (efferocytosis) can unexpectedly promote tumor growth in bone metastases of prostate cancer by stimulating the release of a pro-inflammatory protein.
Biotecnika Times Newspaper 16th Jan 2018shekhar suman
Living microbes have been documented for the first time in polar snow and ice samples. A new study analyzed snow samples from the University of York and found evidence of living bacteria in snowpacks through the presence of methyl iodide, a gas produced by marine bacteria. This challenges the assumption that polar ice cores are sterile and suggests microbial activity could impact the composition of ancient air trapped in ice. The discovery broadens our understanding of where life can survive in extreme environments and could affect the use of ice cores to study past climates.
The FDA has approved the expanded use of the antibiotic Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by several gram-negative bacteria in patients 18 and older. This is the first new antibiotic approved to treat these infections caused by gram-negative bacteria in over 15 years. Clinical trials showed Avycaz to be effective against these infections, including some caused by bacteria producing certain antibiotic resistance enzymes. The approval provides a new treatment option for serious gram-negative infections that is urgently needed.
Biotecnika Times Newspaper 27th November 2017shekhar suman
The article profiles Dr. Karunagaran, the Head of the Department of Biotechnology at IIT Madras. It discusses his illustrious career in biochemistry research and education. It highlights his specialized research in cancer biology and signal transduction. It also summarizes his views on pursuing research careers in biotechnology and the importance of exams like CSIR NET for research aspirations. The article then provides summaries of other research news stories, including the development of water-based herbicides by JNU researchers, a continuous cell culture technique developed by Newcastle University researchers, and the creation of gene-drive mosquitoes using CRISPR/Cas9 gene editing by UC Riverside researchers.
Are you Silently Sabotaging your Job Search ?shekhar suman
The document discusses four underlying issues that can silently sabotage a job search: lack of confidence, fear of rejection, lack of enthusiasm, and lack of direction. It provides advice on each issue to overcome roadblocks to success in the job search. Specifically, it advises developing confidence without overconfidence, facing fear by remembering that fear means death, showing realistic but not overenthusiastic passion for work, and maintaining a unidirectional approach with clear priorities in interviews.
This document contains previously asked questions from spectroscopy exams presented by Dr. Abiram. The questions cover topics in various spectroscopy techniques including infrared spectroscopy, nuclear magnetic resonance spectroscopy, carbon-13 NMR, proton NMR, mass spectrometry, and UV-vis spectroscopy. Answer explanations are provided for some of the questions.
Here is Gabe Whitley's response to my defamation lawsuit for him calling me a rapist and perjurer in court documents.
You have to read it to believe it, but after you read it, you won't believe it. And I included eight examples of defamatory statements/
13062024_First India Newspaper Jaipur.pdfFIRST INDIA
Find Latest India News and Breaking News these days from India on Politics, Business, Entertainment, Technology, Sports, Lifestyle and Coronavirus News in India and the world over that you can't miss. For real time update Visit our social media handle. Read First India NewsPaper in your morning replace. Visit First India.
CLICK:- https://firstindia.co.in/
#First_India_NewsPaper
Essential Tools for Modern PR Business .pptxPragencyuk
Discover the essential tools and strategies for modern PR business success. Learn how to craft compelling news releases, leverage press release sites and news wires, stay updated with PR news, and integrate effective PR practices to enhance your brand's visibility and credibility. Elevate your PR efforts with our comprehensive guide.
Youngest c m in India- Pema Khandu BiographyVoterMood
Pema Khandu, born on August 21, 1979, is an Indian politician and the Chief Minister of Arunachal Pradesh. He is the son of former Chief Minister of Arunachal Pradesh, Dorjee Khandu. Pema Khandu assumed office as the Chief Minister in July 2016, making him one of the youngest Chief Ministers in India at that time.
1. January 1st, 2018.
NEWS - PAGE 3 NEWS - PAGE 4 JOBS, SCHOLARSHIPS &
ADMISSIONS - PAGES 6-11
NEWS - PAGE 2
FDA APPROVES FIRST GENE THERAPY TO
TREAT RARE INHERITED VISION LOSS
NUTRIENT TRANSPORT IN TALL TREES
BIOCON TO INVEST IN UTTAR PRADESH
HEALTH SECTOR, INTENDS TO
ENCOURAGE ENTREPRENEURS IN STATE NEW JOBS AVAILABLE
Scientists Cash In On
Weakness in
Bacterial Cell Wall
Although the multilayered architecture
of the cell envelope of gram-negative bac-
teria was first described in the 1960s, we
are still unraveling the links between the
structure of this cellular component and
its functions in the cell.
The envelope of these bacteria consists
of an inner membrane (IM), a classical
phospholipid bilayer around the cyto-
plasm, and an outer membrane (OM), an
asymmetric structure with phospholip-
ids in the inner leaflet and lipopolysac-
charides in the outer leaflet. The space
between the IM and the OM defines the
periplasm, a cellular compartment that
contains the peptidoglycan, a polymer of
glycan strands cross-linked by short pep-
tides that provides shape and osmotic pro-
tection to cells.
PATH-BREAKING STUDY
Path-Breaking Study, Scientists
Cash In On Weakness in Bacterial
Cell Wall to Fight Ab Resistance
This multilayered envelope, which contrib-
utes to cellular integrity and modulates per-
meability, is required for life and serves as an
interface to the external milieu. Several es-
sential protein machineries are present in the
cell envelope, where they engage in process-
es that are important for envelope assembly
and protection. Many of these machineries
span the periplasm, with components in both
the IM and OM. The pathways that assem-
ble the envelope and that monitor envelope
integrity are tightly coordinated in order to
sense and respond to damage.
Professor Jean–François Collet, of the Uni-
versité Catholique de Louvain, one of the
study’s co-authors, said, “On the wall there is
a protein that serves as a guard, and so when
there are antibiotics coming this protein will
feel that and will then turn inside and reach
another protein on the inner membrane, and
they will communicate.”
Scientists removed the physical connection
between the outer membrane and periplasm
and discovered that the bacteria lost the abili-
ty to sense defects in the envelope.
Drugs that target the envelope structure in
the cell wall may be an effective method for
destroying these cells. Even a slight increase
in the size of the periplam disrupted the com-
munication between the layers of the enve-
lope.
“We showed that if you increase the dis-
tance between the two walls, the protein will
turn inside and try to reach its friends on the
inner wall, but it will not be able to reach
them,” write the authors of the paper.
The team believes that by messing with pro-
teins controlling the distance between mem-
branes, they can disturb the overall architec-
ture of the cell envelope. They are currently
working with drug companies to develop new
substances that are able to disturb bacterial
cell walls and ultimately fight disease.
Vol. 02 NO 1
1
GET THIS NEWSPAPER e-copy VIA WHATSAPP every week
GIVE MISSED CALL TO
080-395-34707
“This work identifies a potential new target
for novel antibacterial therapies that could
be used to treat bacteria that are resistant
to other classes of antibiotics, but there is a
long way to go before this could lead to new
drugs,” said Dr Richard Stabler, co-director
of the London School of Hygiene and Trop-
ical Medicine’s Antimicrobial Resistance
Centre, who was not involved with the study.
Although this research is certainly in its in-
fancy, the scientists believe that if they can
develop necessary methods/techniques to
achieve their hypothesis, then they may have
a valid way to combat multi-drug-resistant
bacteria.
By Disha Padmanabha
2. Vol. 02 NO 1January 1st, 2018.
2
Hearing requires the conversion of acoustic
energy into electrical signals. Sound waves
travel through the ear and wash over the hair
cells of the inner ear, which bend under pres-
sure and send an electrical impulse up the au-
ditory nerve to the brain.
Nearly half of all cases of deafness are due
in some part to genetic factors, and many of
those gene mutations affect the functioning
of hair cells. The most common cause of ge-
netic hearing loss, accounting for 20 percent
of cases, is a recessive connexin 26 mutation
on the GBJ2 gene.
For people with the condition, hearing loss
begins in childhood and deafness ensues
within 10 to 15 years.
A recessive disease mutation requires a
copy of the mutation from both parents. By
contrast, one parent can pass along a dom-
inant disease mutation like the one in the
TMC1 gene, cause of 4 to 8 percent of cas-
es of genetic hearing loss. TMC1 creates a
defect in a protein that helps convert sounds
into electrical signals, while the healthy copy
of the gene is simply ignored.
Now, in a ground breaking study, research-
ers have been able to prevent deafness in
mice using gene editing.
“We’re hopeful that our results will help
guide the development of similar strategies,”
says David Liu, a genetic engineer at Broad
Institute, the Massachusetts Institute of Tech-
nology and Harvard University.
The research relies the CRISPR–Cas9 edit-
ing system to knock out a mutant form of the
“Today’s approval marks another first in the
field of gene therapy — both in how the ther-
apy works and in expanding the use of gene
therapy beyond the treatment of cancer to the
treatment of vision loss — and this milestone
reinforces the potential of this breakthrough
approach in treating a wide-range of chal-
lenging diseases. The culmination of decades
of research has resulted in three gene therapy
approvals this year for patients with serious
and rare diseases. I believe gene therapy will
become a mainstay in treating, and maybe
curing, many of our most devastating and in-
tractable illnesses,” said FDA Commissioner
Scott Gottlieb, M.D.
“We’re at a turning point when it comes to
this novel form of therapy and at the FDA,
we’re focused on establishing the right pol-
icy framework to capitalize on this scientif-
ic opening. Next year, we’ll begin issuing a
suite of disease-specific guidance documents
on the development of specific gene therapy
products to lay out modern and more efficient
parameters — including new clinical meas-
ures — for the evaluation and review of gene
gene Tmc1. In doing so, it lays out a potential
pathway for treating other genetic causes of
hearing loss.
Liu performed his experiments on a type of
mouse known as a Beethoven mouse. These
mice carry a defect that causes them to lose
their hearing starting early in life. It’s prob-
ably not what caused the famous German
composer Ludwig von Beethoven’s deafness.
Still, the same defect does cause deafness in
some families.
The researchers then injected the gene edit-
ing tool inside the ears of the live mice; the
molecular scissors were able to precisely cut
the disease-causing copy of the gene with-
out disrupting the healthy copy. Eight weeks
after the injection, hair cells in treated ears
resembled those in healthy animals – dense-
ly packed and tufted with hairlike bundles.
The hair cells of untreated mice, in contrast,
looked damaged and sparse.
Then the researchers conducted a hearing
test on the mice by placing electrodes on their
heads and monitoring the activity of brain re-
gions involved in hearing. Researchers need-
ed more sound to spark brain activity in un-
treated mice compared with treated mice, the
team found.
On average, after four weeks, treated ears
could hear sounds about 15 decibels lower
than untreated ears. “That’s roughly the dif-
ference between a quiet conversation and a
garbage disposal,” Liu said.
Because CRISPR-Cas9 can be guided to
any gene, rewriting DNA with gene editing
Breakthrough Alert:
Researchers Edit Faulty
Gene to Disrupt Hearing
Loss
FDAApproves First Gene
Therapy to Treat Rare
Inherited Vision Loss
By Disha Padmanabha
Treatment with Crispr was shown to preserve sound-detecting hairs in the inner ear of mice (white box, left).
Without the treatment, these hairs disappear (white box, right). Photograph: Gao et al. /Nature 2017
therapy for different high-priority diseases
where the platform is being targeted.”
The Food and Drug Administration has
now approved Spark Therapeutics’Luxturna,
the first directly administered gene therapy
approved in the U.S. that targets a disease
caused by mutations in a specific gene- Leber
congenital amaurosis.
It is the first FDA-approved gene therapy
for a genetic disease, the first and only phar-
macologic treatment for an inherited retinal
disease (IRD) and the first adeno-associated
virus (AAV) vector gene therapy approved in
the U.S.
Luxturna is a gene therapy that’s directly
administered to patients who have a condi-
tion called biallelic RPE65 mutation-associ-
ated retinal dystrophy. The disorder is caused
by defects in a gene which helps produce a
protein critical to normal vision. With Lux-
turna, a healthy copy of the gene is inserted
into retinal cells (with the help of engineered
viruses) in order to produce the necessary
protein and restore vision.
The defective gene that causes the disease
can be passed down for generations undetect-
ed before suddenly appearing when a child
inherits a copy from both parents. Only a few
thousand people in the U.S. are thought to
have the condition.
Luxturna is delivered via two injections —
one for each eye — that replace the defec-
tive gene that prevents the retina, tissue at the
back of the eye, from converting light into
electronic signals sent to the brain.
The Philadelphia-based Spark Therapeutics
said it will announce its price in early Jan-
uary, but suggested its own analysis put the
value of the therapy in the $1-million-dollar
range. Key to the company’s reasoning is the
assumption that Luxturna will be given once,
with lasting benefits.
“This approval is a watershed milestone,”
said Benjamin Yerxa, Ph.D., chief executive
officer at the Foundation Fighting Blindness
(FFB), a nonprofit organization focused on
research for preventing and treating blind-
ness caused by IRDs. “For people with an
inherited retinal disease and for other patient
communities, this decision may create im-
portant momentum for investigational gene
therapies. The Foundation is very pleased
that our early investments in research have
helped lead to the approval of Luxturna. And
we encourage patients to get genetic testing
so they can help advance the research and
possibly benefit from this treatment or other
gene treatments as they emerge.”
By Disha Padmanabha
is akin to rewriting software. Other forms of
deafness attributable to an errant copy of a
single gene might also be ameliorated using
the same technique. Altogether such cases
amount to about 20 percent of genetic deaf-
ness.
Lustig, who works with patients with hear-
ing loss every day, says Liu’s results are “sig-
nificant” and offer hope for gene editing as
a treatment. “It’s not around the corner,” he
says, “but we’re on the pathway.”
Moving forward, delivery methods, im-
proved efficacy, and an investigation into
potential side effects are top priorities. These
steps are crucial if we’re to find out whether
the procedure could give medical profession-
als a way to restore their patients’ hearing.
“There’s still quite a bit of work to do be-
fore this approach might be used in humans,”
Liu said.
3. Vol. 02 NO 1 January 1st, 2018.
3
Tall people are literally the giants among
men, walking around with near total impu-
nity, being given every advantage along the
way. But sometimes, the blessing can also be
a curse. Also, while on the topic, scientists
have always wondered how tall trees accom-
plish the task of moving nutrients over long
distances.
Trees present a critical challenge to
long-distance transport because as a tree
grows in height and the transport pathway in-
creases in length, the hydraulic resistance of
the vascular tissue should increase.
Although species that actively load sugars
into their phloem, such as vines and herbs,
can increase the driving force for transport
as they elongate, it is possible that many
trees cannot generate high turgor pressures
because they do not use transporters to load
sugar into the phloem.
Therefore, researchers at the at the Harvard
University examining how trees can main-
tain efficient carbohydrate transport as they
grow taller by analysing sieve tube anato-
my, including sieve plate geometry, using
recently developed preparation and imaging
techniques, and by measuring the turgor pres-
sures in the leaves of a tall tree in situ.
They also found that “the pressures that de-
velop in the leaves of a mature red oak tree
are sufficient to drive transport of sugars
all the way to the roots,” said Noel Michele
Holbrook, a research team member who is
NUTRIENT TRANSPORT IN TALL TREES
By Disha Padmanabha
a professor of biology and Charles Bullard
Professor of Forestry in the Department of
Organismic and Evolutionary Biology at
Harvard.
“We now have evidence that all plants —
both small and tall — use the same mecha-
nism to transport sugars,” Holbrook said.
“And we now understand how trees can get
tall without running into transport limita-
tions associated with their size. Our research
answers a multidecade debate about how
sugars are transported in trees.”
The research team took extensive meas-
urements of the structure of the sugar-con-
ducting tubes along the length of many trees,
while also measuring the hydraulic resistance
in these tubes.
“To sample the phloem, one of the most del-
icate and easily wounded tissues in the plant,
we had to cut away the outer bark. In the big
stems, we did this using a hammer and a chis-
el, not tools that we typically use in the lab,”
Holbrook said. The team also measured the
pressures in the leaves of a tall tree by using
a fluorescent microscope they hoisted up into
the tree canopy.
“We found that the resistance to moving
the sugar-rich phloem sap does not increase
linearly with the transport length because
the phloem transport cells in the main stem,
especially toward the base, were wider and
longer and also had more porous ‘sieve
plates,’” Holbrook said. “Thus, the pressures
needed to drive phloem transport are much
lower than had been predicted.”
The team believes that their work holds im-
portant implications for food production.
“The majority of food generated by pho-
tosynthesis moves through the phloem,” she
said. “If there are ways to make plants more
productive in terms of having higher photo-
synthesis, then they will also need the ability
to transport those sugars to the tissues that
we eat. Thus, understanding how plants make
efficient transport systems could contribute
toward the development of higher-yielding
crops and more productive trees.”
YOUR CSIR NET PREP PARTNER
Michael Knoblauch, a plant cell biologist from Washington State University, led the development of the instru-
ments used in the research.
4. Vol. 02 NO 1January 1st, 2018.
4
A Complete Look at the
Protein behind Sense of
Touch
Often ignored when we talk about our fun-
damental senses, the sensation of touch is
a fundamental part of our daily experience.
From temperature to texture, your sense of
touch has been in constant communication
with your brain.
In 2016, a team of scientists revealed that
a protein first discovered at TSRI in 2010 is
directly responsible for sensing touch. Now,
the same team at The Scripps Research Insti-
tute (TSRI) have solved the mystery of the
structure of Piezo1, a member of a family of
proteins that convert physical stimuli such as
touch or blood flow into chemical signals.
“This structure provides a fundamental un-
derstanding of how proteins sense mechani-
cal force, and will shed light on regions with-
in Piezo1 that can be targeted using small
molecules or antibodies,” says Ardem Pata-
poutian, PhD, a TSRI professor and Howard
Hughes Medical Institute investigator, who
co-led the new study with TSRI Professor An-
drew Ward, PhD.
Piezo1 and Piezo2 are mechanically acti-
vated ion channels that mediate touch per-
ception, proprioception and vascular devel-
opment. Piezos are distinct from other ion
channels and their structure remains poorly
defined, impeding detailed study of their gat-
ing and ion permeation properties.
When Peizo1 senses mechanical force, it
opens to allow ions to pass into the cell, start-
ing a chain of events that send a signal to the
brain—in other words; Piezo proteins control
the sensation of touch.
In order to further study this proteins’ func-
tion and structure in detail, the team carried
out with a high-resolution imaging technique
called cryo-electron microscopy (cryoEM),
shows that Piezo1 is made up of three curved
“blades” circling a central pore. The research-
ers believe these blades move in response to
mechanical force, which opens and closes the
pore to let ions through to send the signal to
communicate touch. A beam-like structure
serves as the backbone for each blade. An
“anchor domain” surrounds the pore where
the blades meet the middle.
The Piezo1 structure is unique because it
appears to be an “all-in-one” protein, mean-
ing it does not need to connect with other
proteins or cell structures to do its job trans-
mitting a signal.
The researchers state that the next step in
this research is to examine the overall archi-
tecture of Piezo1 and determine how each
piece works. They hope to look at this protein
in different conformations besides the closed
conformation seen in the current study.
Biocon to Invest in Uttar
Pradesh Health Sector,
Intends to Encourage
Entrepreneurs in State
Bengaluru-based biotech, Biocon, headed
by Kiran Mazumdar-Shaw reportedly is to in-
vest in the healthcare centres of Uttar Pradesh
and encourage entrepreneurs in the biotech
space, especially the startups, to work in the
state.
“She said that a survey should be conduct-
ed in all districts of UP, including Gorakh-
pur, for starting e-health care centres under
a pilot project. She further suggested that a
campaign be launched to attract investors
in the health sector,” said a member of UP’s
delegation which was in the city as part of
the road show organised by the UP govern-
mentas a precursor to the investors’ summit
in February 2018.
Industrial Development Minister Satish
Mahana said during the road show that un-
der the IT policy in UP, the startup carps fund
has been increased from Rs. 100 crores to Rs.
1000 crores. Establishment and Industrial
Development Commissioner Anup Chandra
Pandey said that the state government is giv-
ing the status of specific industry to the plants
being set up for solar power generation. All
solar energy production projects have been
granted exemption from obtaining environ-
mental nod. There is a separate session for
NRI under the UP Investors Summit.
“Project developers will be provided with
‘no-objection certificates’, full exemption in
stamp fee and electricity cess for 10 years
on purchasing ceiling land of at least 5.058
hectares. All solar energy generation projects
will be given exemption from obtaining envi-
ronmental NOC,” he said. By Disha Padmanabha
By Disha Padmanabha
5. Vol. 02 NO 1 January 1st, 2018.
5
Yale Scientists Develop
Simple Test to Identify
Viral Infections
Lights, Plants, Action:
Ancient Algae Analysis
Reveals Photosynthesis to
be a 1.25 Billion Years-Old
Process
Upper respiratory illnesses are common, yet
there is no rapid diagnostic test to confirm
more than a handful of common viruses as
the cause. To identify biomarkers, or indica-
tors, of viral infection applicable to many dif-
ferent respiratory viruses, researchers at the
Yale University have developed a new test.
The test measures Ribonucleic acid or pro-
tein molecules in human cells can accurately
identify viral infection as a cause of respira-
tory symptoms. Performed with a simple na-
sal swab, the test might be a quicker, cheaper
way to diagnose respiratory viral illnesses
than current methods, said study author Dr.
Ellen Foxman, professor of laboratory medi-
cine at the Yale School of Medicine.
When developed into a measure that can be
used in a physician’s office, it will contribute
significantly to the treatment of very sick pa-
tients and young children, and will help pre-
vent the misuse of antibiotics.
“It’s a simpler test and more cost-effective
for looking at viral infection,” said author
Ellen Foxman.
“Instead of looking for individual viruses,
our test asks the question: ‘Is the body fight-
ing a virus?’” said Foxman. “We found we
can answer that question very well.”
In the process of developing this test, the
team identified three RNAs, and two proteins,
that are “turned on” by a virus. They then in-
vestigated whether measuring the expression
of the genes, or levels of the proteins, could
predict the presence of a viral infection.
The researchers found that the RNAs and
proteins were both accurate predictors of res-
piratory viral infection, confirmed by subse-
quent testing for common viruses. The RNAs
predicted viral infection with 97% accuracy.
This method also picked up viruses that are
not identified by many current lab tests, they
said.
The research team’s goal is to create a gene-
or protein-based test available for general use
within one to five years, Foxman said. Also,
a major upside of the test is that it could help
limit the unnecessary prescribing of antibiot-
ics. Although antibiotics only work on bac-
terial infections, they are often incorrectly
prescribed for viral infections.
“There’s a big problem with antibiotic over-
use,” Foxman said. “Taking antibiotics when
you don’t need them can be harmful, espe-
cially for kids.”
The team has a patent pending on the test,
and the eventual goal is for it to become a
widely used diagnostic tool. By Disha Padmanabha
If it wasn’t for photosynthesis, we’d all be
dead. Most plants would cease to exist, car-
bon dioxide would flood the air, and oxygen
wouldn’t replenish. Suffice it to say we’d all
be screwed.
It is the ultimate source for the energy that
fuels us, the oxygen we breathe and the or-
ganic molecules that form our bodies. It is
the cornerstone for familiar ecosystems such
as tropical forests, grasslands and coral reefs.
In fact, each of these terms in turn places an
emphasis on the photosynthetic organisms
forming the foundation of their respective
ecosystem.
Now, according to a new study by research-
ers at the McGill University, the process of
photosynthesis in plants first took place 1.25
billion years ago.
The world’s oldest algae fossils are a billion
years old, according to the new analysis by
earth scientists at the University. Based on
this finding, they also estimate that the basis
for photosynthesis in today’s plants was set in
place 1.25 billion years ago.
The algae Bangiomorpha pubescens was
discovered in Arctic Canada in 1990 and has
been at the center of multiple studies, but
scientists haven’t been able to figure out pre-
cisely its age. Some estimates pegged its age
somewhere between 720 million and 1.2 bil-
lion years. But the latest study resolves this
confusion and puts the age of the algae and
basis of photosynthesis at 1.25 billion years.
In order to pinpoint the fossils’ age, the re-
searchers pitched camp in a rugged area of
remote Baffin Island, where Bangiomorpha
pubescens fossils have been found there,
despite the occasional August blizzard and
tent-collapsing winds, they collected sam-
ples of black shale from rock layers that
sandwiched the rock unit containing fossils
of the alga. Using the Rhenium-Osmium (or
Re-Os) dating technique, applied increasing-
ly to sedimentary rocks in recent years, they
determined that the rocks are 1.047 billion
years old.
“That’s 150 million years younger than
commonly held estimates, and confirms that
this fossil is spectacular,” says Galen Hal-
verson, senior author of the study and an as-
sociate professor in McGill’s Department of
Earth and Planetary Sciences. “This will en-
able scientists to make more precise assess-
ments of the early evolution of eukaryotes,”
the celled organisms that include plants and
animals.
Because Bangiomorpha pubescens is nearly
identical to modern red algae, scientists have
previously determined that the ancient alga,
like green plants, used sunlight to synthesize
nutrients from carbon dioxide and water.
Scientists have also established that the
chloroplast, the structure in plant cells that is
the site of photosynthesis, was created when
a eukaryote long ago engulfed a simple bac-
terium that was photosynthetic. The eukary-
ote then managed to pass that DNA along to
its descendants, including the plants and trees
that produce most of the world’s biomass to-
day.
“We expect and hope that other scientists
will plug this age for Bangiomorpha pubes-
cens into their own molecular clocks to cal-
culate the timing of important evolutionary
events and test our results,” says McGill
PhD student Timothy Gibson, lead author of
the new study. “If other scientists envision a
better way to calculate when the chloroplast
emerged, the scientific community will even-
tually decide which estimate seems more rea-
sonable and find new ways to test it.”
By Disha Padmanabha
6. Vol. 02 NO 1January 1st, 2018.
6
TATA INSTITUTE OF FUNDAMEN-
TAL RESEARCH
(Autonomous Institution of the Depart-
ment of Atomic Energy, Government of
India)Sy.No.36/P, Gopanpally Village, Ser-
ilingampally Mandal,
Ranga Reddy Dist. Hyderabad – 500 107
Tel: +91(0) 40 2020 3040 Website: www.
tifrh.res.in
Applications are invited for the following
post tenable at Hyderabad. Please visit our
website for application details and prescribed
requirements http://www.tifrh.res.in/index.
php/staff-positions/.
Name of the Post : Project Scientific Of-
ficer (C)
Age Below : 28
Pay Band + Grade Pay (Rs) : Rs. 52000/-
TME : Rs. 52000/- (including HRA)
Project Scientific Officer (C):
Temporary for one year and may be re-
newed each year upto a total period of three
years depending upon performance and re-
quirement.
Essential Qualifications :
Post Graduate in any field of Biology with
60% marks (in aggregate)
Essential Experience :
Minimum 1-2 years’ experience in Wet
Laboratory Research.
Desirable Experience :
Excellent command of written and verbal
communication in English.
The St. John’s Research Institute (SJRI) is
a part of the St John’s National Academy of
Health Sciences, which is run by the CBCI
Society for Medical Education. From its in-
ception, St. John’s has set before it an ideal
of excellence in academic courses as well as
service to society as a result of which it has
truly become holistic both in its outlook and
in its approach to the problems of community
JOBS
TIFR RECRUITING PROJECT SCIENTIFIC
OFFICER | SALARY OF RS. 52,000/- P.M.
FRESHERS JOB : JRF POSITION @ ST.
JOHN’S RESEARCH INSTITUTE (SJRI) |
MSC LIFE SCIENCES APPLY
Job Requirement:
• Assisting biology faculty in the devel-
opment and implementation of stand-
ard operating procedures (SOPs) for
safe, responsible and ethical conduct of
biological laboratory research at TIFR
Hyderabad.
• Training biology students and staff in
safe, responsible and ethical conduct
of biological research at TIFR Hydera-
bad via classroom as well as laboratory
presentations.
• Arranging the training of new faculty,
staff and trainees in the proper use of
biological research facilities at TIFR
Hyderabad and ensuring compliance
with the institutional SOPs.
• Overseeing the constitution of institu-
tional biological and research safety
and ethics committees by inviting ap-
propriate member scientists.
• Interfacing with respective government
agencies to ensure timely submission
and review of the specific laboratory
research and safety protocols.
• Coordinating with vendors, TIFR ad-
ministration and scientists for the ten-
dering, acquisition and maintenance of
major common biological equipment,
supplies and establishment of infra-
structure for common biological re-
search areas
How to Apply :
General Information:
Higher starting salary could be considered
for deserving candidates for the above posts.
Selected candidates are liable to be trans-
ferred to other Centres / Field Stations of the
Institute, if required.
Prescribed age should not exceed as on July
1, 2017 for the above posts.
Post for the general category (Unreserved)
– SC/ST/OBC/PWD (Persons with Disabili-
ties) candidates can also apply.
Selected candidate may have to work in
shifts/outside office hours and on Saturdays/
Sundays and holidays.
Applications from the candidates will be ac-
cepted ONLY ON-LINE.
Candidates applying for above posts and
who are eligible for age relaxation as per
extant GOI rules are required to submit ap-
plications by POST, along with a copy of rel-
evant certificate in support of age relaxation
(for example ex-servicemen, persons with
disabilities etc.). [SC, ST & OBC candidates
applying for unreserved posts are not eligible
for age relaxation and should apply online].
Incomplete applications and applications
without photocopy of certificates in support
of age relaxation and applications received
after the last date shall not be considered.
Applicants in Government/Semi-Govern-
ment/Public Sector Undertaking must apply
through proper channel. Applicants, who do
not send their applications through proper
channel, if called, will be able to participate
in the recruitment process only upon submis-
sion of the NOC from the competent author-
ity. However, an advance copy of application
along with relevant enclosures may be sub-
mitted by post before 20 January 2018. Such
applicants are not required to apply online.
• On-line applications must be submitted
by 20 January 2018 and applications by
post must reach In-Charge, Establish-
ment by 20 January 2018. Applicants
who are required to send the applica-
tions by post must super scribe the post
applied for, advertisement No. & serial
number of the post on the envelope.
The format of the application is as pre-
scribed for on-line applications.
Note:
The candidates are required to produce fol-
lowing original documents with copies at
the time of the recruitment process:
a. Printout of online application form.
b. Identity proof (Aadhar Card/ Election
Card / Pan Card / Passport / Driving
License).
c. Date of birth / Proof of age.
d. Educational Qualification (all mark
sheets and certificates).
e. Experience Certificate/s.
f. Conduct certificates from two respectable
persons
g. Candidates applying for the above post
reserved for Persons with Disability
(HH/OH) should be suffering from not less
than 40% of the relevant disability for the
benefit of reservation. Candidates will have
to submit a Disability Certificate issued by
thecompetent authority in the prescribed for-
mat. PWD candidates belonging to SC/ST/
OBC will be given further age relaxation as
per extant GOI rules.
• Outstation candidates called for inter-
view for the above posts will be paid
single second class (non air-condi-
tioned) return train fare for the journey
by the shortest route from the nearest
railway station of their place of resi-
dence to the nearest railway station of
the place of interview on the produc-
tion of photocopies of onward and re-
turn journey tickets.
• The Institute reserves the right to re-
strict the number of candidates for the
recruitment process to a reasonable
limit on the basis of qualifications and
experience higher than the minimum
prescribed in the advertisement. Mere
fulfilling the essential and desirable
qualifications will not entitle an ap-
plicant to be called for the recruitment
process. More vacancies may also be
filled through this advertisement. The
Institute reserves the right not to fill
any/some posts herein advertised. Can-
vassing in any form shall disqualify the
candidate.
Important Dates :
Registration begins : 22-12-2017
Registration closes : 20-01-2018
health.
Post:
Junior Research Fellow (JRF)
Project Title:
Analytical Project
Division :
Nutrition
Contact person:
Lincy Thomas
Contact No. +91-80-49467010 / 49467011
Qualifications:
B.Sc. / M.Sc. Nutrition / Life Sciences
Experience :
Fresher
Next Page>>>>
7. Vol. 02 NO 1 January 1st, 2018.
7
Languages :
English and Kannada
Location :
Bangalore, Karnataka
No. of Vacancies: 1
Salary:
Rs.25000/-pm (all inclusive)
Brief Description about the Project:
Calcium intervention trial during pregnan-
Saha Institute of Nuclear Physics, an au-
tonomous institute under the auspices of the
Dept of Atomic Energy, GoI, invites applica-
tions on e-mail from candidates for tempo-
rary positions of Research Associates (RAs)
in the various Divisions of the Institute.
Name of the Position :
Research Associate (RA)
No. of Positions : 01
Name of Division :
Crystallography & Molecular Biology Di-
vision
Age :
Maximum 35 years as on last date of receiv-
ing the application.
Panacea Biotec is a leading research
based Health Management Company. We
are engaged in research, development,
manufacture & marketing of Vaccines,
Bio-Pharmaceuticals and Pharmaceuticals
(Rx & OTC) of international quality and
Health Services. All Panacea Biotec plants
are accredited by international agencies
and they follow current Good Manufac-
turing Practices, as per WHO guidelines.
We offer stimulating work environment &
a career that spells growth. In tune with our
plans, we require young, aggressive, dynam-
ic, high performing and result oriented pro-
fessional.
Designation :
Sr. Scientific Officer /Scientific Of-
ficer-Quality Control-Micro
Job Description :
cy – the pregnant women attending BBMP
hospitals will receive 2 different dosages of
calcium supplement. They will be followed
up during pregnancy for outcome measures
such as preeclampsia and preterm.
Core Responsibilities:
• Recruitment of pregnant women
• Data collection and follow up during
pregnancy and of the infant post-deliv-
ery
• Channelizing the study protocol with
social workers and other team mem-
bers for completion of various study
milestones
• Reporting day-to-day activities to the
study co-ordinator
Specific Activities:
• At hospital OPD – recruitment of sub-
jects, data collection and follow up
• Channelizing with the social work-
er and lab technician, home visits for
supplement distribution, compliance
monitoring
• Data entry
Key Skills:
• Basic personnel rapport maintaining
skills
• Record maintenance and home visits
• Compliance recording
• Basic computer knowledge
• Willing to learn newer techniques
How To Apply:
E-mail cover letter, CV and the names &
contact details of referees to pratibha@
sjri.res.in, molly.j@sjri.res.in and cc to
hr@sjri.res.in
For more information, please visit our
website www.sjri.res.in
Application Due Date: 11th January,
2018
FRESHERS JOB : PHD CANDIDATES APPLY
@ SAHA INSTITUTE OF NUCLEAR
PHYSICS FOR RESEARCH POSITION
SCIENTIFIC OFFICER – QUALITY CONTROL
(MICRO) @ PANACEA BIOTEC |
APPLY ONLINE
Tenure :
The tenure of Research Associates may be
decided by the Institute as per overall sanc-
tions available to them for this purpose. Such
appointments will be for a period of two (02)
years with the possibility of extension for one
(01) more year.
Associateship:
(a) Rs. 36, 000/- PM for RA-1+HRA
(b) Rs.32, 000/- PM, for scholars who have
submitted Ph.D. thesis and are yet to receive
their Ph.D degree (provisional or otherwise)
+HRA
(c) Rs 38,000/- PM for RA-2+HRA
In addition the other admissible benefits are
applicable.
Essential Qualification :
Ph.D in Physical and Biophysical sciences
or Scholars who have submitted Ph.D. thesis
and are yet to receive their Ph.D degree (pro-
visional or otherwise)
Desirable Qualifications :
Candidates with fresh PhD having working
experience in different biological aspects of
proteins.
How to Apply:
Procedure for Applying Interested and eligi-
ble candidates should apply by email only to
vacancy.ra@saha.ac.in with the subject mat-
ter ‘APPLICATION FOR THE POSITION
OF RA-2017’.
A copy of the same is to be forwarded to the
choice of division as per list.
Crystallography & Molecular Biology Divi-
sion(C&MB) : cmb.ra@saha.ac.in
The following details are to be appended in
the application:
(a) Complete Bio-data Proforma with
e-mail ID/ Phone No.
(b) Details of qualification i.e. Examination
passed, year, division, and
percentage of marks from Graduation on-
wards
(c) Details of Publications
(d) Details of Conferences/workshops at-
tended
(e) Each application should include the de-
tails of three (03) referees with contact
details including email.
All applications are to be received on or
before 31st January, 2018.
Please keep track of details/amendments
on the website
• Responsible for performing the sterility
testing of active raw materials from the
production blocks and maintaining its
records.
• To perform sterility test for pre ster-
ilized articles and maintaining its re-
cords.
• To perform the activities related to pro-
cess validations and maintaining its re-
cords.
• To performs in process samples
• To execute qualification/validation
protocol of equipment’s.
• To prepare product specification and
standards test procedures.
• To prepare validation /qualification
protocol of equipment’s.
• To review the log of media preparation
,environment monitoring ,critical utili-
ties testing, in-process testing, growth
promotion test, culture maintenance
and other logs of microbiology lab
• To prepare procedural/operational/
product specific standard operating
procedures.
• To identify the isolates using API Kit
and make the library of the microor-
ganisms isolated from the sterility fail-
ure/environment/critical utilities.
• To maintain the inventories of The Lab
• To qualify the microbiologist for the
various testing done in the microbiol-
ogy lab
• To executive All QMS.
Experience :
1-6 Years
Age :
25-35 Years
Industry Type :
Biotechnology/ Microbiology
Functional Area :
In process Quality Control / Audit and
Compliance
Education :
MSc-Biotechnology, MSc –Microbiology,
B.Tech.-Biotechnology
Compensation :
At par with the Industry
Department :
Quality Control -Microbiology
Location :
Lalru -Punjab
How to Apply :
Email : pradeepupadhyay@PANERABI-
OTEC.COM
8. Vol. 02 NO 1January 1st, 2018.
8
WWF-India, one of the largest conservation
organizations, engaged in wildlife and nature
conservation in the country, invites applica-
tions for the post of Project Officer-Great In-
dian Bustard Conservation, from candidates
with an inherent sensitivity towards the con-
servation of nature and environment.
The great Indian bustard is a Critically En-
dangered species which needs urgent conser-
vation measures. WWF-India has been part-
nering with the Rajasthan Forest Department
and local communities for conservation of
the great Indian bustard in the Desert Na-
tional Park. A dynamic biologist, with a zeal
to work on one of the Critically Endangered
birds in one of the most spectacular habitats,
is needed by WWF-India. The candidate
is expected to work for field surveys, data
analysis and report preparation for GIB and
its habitat in the DNP. Some of the activities
have already been undertaken and advanced
planning for securing GIB habitats is one of
the tasks for the candidate.
Job Title : Project Officer- GIB Conser-
vation
Location :
Jaisalmer, Rajasthan
Indian Institute of Science Education and
Research Pune is a premier autonomous In-
stitution established by the Ministry of Hu-
man Resource Development, Government of
India, for promotion of high quality science
education and research in the country.
Institute invites applications from Indian
nationals having excellent academic record
and relevant work experience for the follow-
ing position purely on temporary and con-
tractual basis under the funded project:
Job Title – Project Assistant / Project Fel-
low
Project Code – 30815218
No.of.Posts – 1
Project Title:
“Characterization and comprehensive ge-
nome-wide analysis of histone deacetylase,
PfHda1 that may regulate expression of var
genes involved in virulence and
pathogenicity of Plasmodium falciparum”.
Age Limit:
Not more than 28 years as on closing date
of advertisement
BIOSCIENCES PROJECT OFFICER
RECRUITMENT
@ WWF – WORLD WILDLIFE FUND
The Job Profile:
Program Implementation and Technical
Support
• Carry out the field surveys on GIBs and
their habitats in the DNP.
• Assist the Forest Department and stake-
holders in field surveys, data analysis
and report preparation with conserva-
tion recommendations.
• To assess factors that are attributed to
putting pressures on long term survival
of GIB.
• Assist the state forest department in
implementing the recommendations
for GIB conservation.
• Regularly update supervisors on pro-
gress.
• Responsible for technical reporting
pertaining to GIB conservation initia-
tives carried out by WWF-India and its
partners in and around DNP.
Networking, Coordination and Commu-
nication
• Coordinate with supervisors, as well
as communication team at WWF-India
Secretariat for communicating pro-
gress as well as success stories from
the project area.
• Capacity building of the forest depart-
ment personnel in DNP on field sur-
veys, data analysis as well as report
preparation.
• Regularly interact with various Govt.
department(s), and community groups
and other stakeholders for planning out
and implementation of project activ-
ities and updating them with the pro-
gress as and when required.
• Analyze information collected from
field and prepare technical reports as
per requirement.
• Publish scientific papers on the tiger
monitoring in the peer reviewed jour-
nals.
• The candidate will be responsible for
effective liasoning with stakeholders
including Govt. department(s), Institu-
tion(s), and NGOs for any issues per-
taining to planning and implementation
of project activities.
Qualifications, Experience and compe-
tencies required:
• M.Sc. in Wildlife Science/ Bio-Science
or related subject from a reputed Uni-
versity in India or abroad.
• At least two years’ experience in moni-
toring Endangered/ Threatened species
and their habitats, particularly in the
state of Rajasthan/ Madhya Pradesh/
Gujarat needed.
Apply Via Email to: recruitments@wwfin-
dia.net
Submission Details :
Please submit an up-to-date CV (mention-
ing your full name in the resume attachment),
giving details regarding compensation re-
ceived in the present assignment, expected
salary, and three references.
Last Date for sending applications: 5th
January, 2018
In order to ensure that your application is
sorted correctly, please mention “Project Of-
ficer-GIB Conservation” in the subject line.
The vacancy is open to Indian Nationals only.
Applications of only the short listed candi-
dates will be acknowledged.
WWF-India is an equal opportunities
employer. Applications from qualified
women are encouraged.
Remuneration will be competitive with In-
dian NGO pay scales and will depend upon
candidate’s experience levels and the over-
all WWF-India salary structure. WWF-India
does not provide housing, telephone or vehi-
cle facilities
INNOVATIVE YOUNG BIOTECHNOLOGIST
AWARD FUNDED PROJECT POST
@ IISER PUNE
Tenure of Appointment:
Up to December 22, 2018
Consolidated Emoluments:
Starting from Rs. 16,000/- to Rs. 28,000/- +
30% HRA per month based on qualification /
valid CSIR NET / GATE or equivalent score-
card and based on experience.
Qualifications:
M. Sc. / M. Tech in Life Sciences from a
recognized University / Institute with a con-
sistent first class academic record ( with
minimum 60% marks) and relevant research
experience as evidenced from thesis / disser-
tation carried out in a reputed scientific in-
stitution.
Preference :
Hands on experience with Plasmodium and
basic molecular biology techniques. Practical
experience in gene cloning, assay develop-
ment and protein purification will be an add-
ed advantage.
How to Apply:
• Interested candidates should send the
application by email in the prescribed
format
• available below this advertisement
(convert into PDF Format) addressed
to bio_app@iiserpune.ac.in on or be-
fore January 10, 2018. Please mention
“Project Assistant / Project Fellow,
Proj. Code: 30815218” in the subject
line of the email.
• The list of the shortlisted candidates for
selection process with details of date,
time and venue will be put up on the
Institute website below this advertise-
ment and candidates will be informed
by e-mail only.
• The PDF of the application form sent
by email must be printed, signed and
dated by the applicant along with re-
cent (no less than 6 months) passport
size photograph and photocopies of
relevant certificates and other testimo-
nials in support of age, qualification,
experience etc. will be collected at the
time of selection process. Applicant
must bring all the original certificates
at the time of selection process for the
purpose of verification, along with one
set of photocopies.
Application Deadline – January 10, 2018
www.biotecnika.org
9. Vol. 02 NO 1 January 1st, 2018.
9
INTERNSHIP / SCHOLARSHIP
Ministry of Science & Technology
Department of Science & Technology
Women Scientists Scheme-C (WOS-C)
(Internship in Intellectual Property
Rights)
Call for Applications- 10th Batch
Women Scientist Scheme (WOS) is a flag-
ship programme of KIRAN Division of De-
partment of Science & Technology (DST).
Through one of its components- ‘Women
Scientist Scheme-C (WOS-C)’- it provides
one year on-the-job training in the area of
Intellectual Property Rights (IPR). Patent Fa-
cilitating Centre (PFC) of Technology Infor-
mation, Forecasting and Assessment Council
(TIFAC) has been entrusted with implemen-
tation of WOS-C
Eligibility Criteria:
• (1) Women with Indian citizenship (2)
Minimum essential qualification: Mas-
ter of Science; Bachelors in Engineer-
ing/Technology or equivalent.
• Age: Minimum 27 years; Maximum 45
years as on 01-01-2018
• Note: a) Women in permanent position
are not eligible to apply and b) those
who have already undergone training
(partially or fully) in any of the earlier
batches or those who are undergoing
training in the ongoing batch are not
eligible to apply.
• Desirable qualification: a) Proficiency
in handling computerized database,
collection, collation, analysis and re-
port preparation, (b) basic understand-
ing of various IPR aspects & issues
with logical aptitude towards scientif-
ic developments across the world and
experience in research, preparation of
project reports, term papers and similar
activities.
Stipend:
M.Sc in Basic or Applied Sciences/B.Tech/
MBBS or equivalent degree : Rs.20,000/- pm
M.Phil/M.Tech/M.Pharm/M.V.Sc or equiv-
alent degree : Rs.25,000/- pm
Ph.D in Basic or Applied Sciences or equiv-
alent degree : Rs.30,000/- pm
Selection & Training Procedure: An on-line
examination will be conducted at various cen-
tres throughout the country. Based on exam
merit, candidates will be called for interview
for final selection. During training, selected
About the scheme:
The “Back-to-Lab” programme of Wom-
en Scientists Division offers Research and
Post-Doctoral Fellowship to women who
have break in their career, to facilitate their
re-entry in science research. The fellowship
is provided normally for a period of 3 years.
The selected Research/Post-Doctoral Fellow
has to work in a reputed research institution
under the guidance of a Scientist Mentor,
who is a permanent faculty of the institute.
RESEARCH FELLOWSHIP
Objectives:
To provide Research Fellowship for women
research scholars who had to undergo break
during the course of their Ph.D. programme
due to family commitments or other valid rea-
sons, so as to facilitate re-entry in research.
Who can apply?
Applicants should satisfy the following
conditions.
Applications Invited : India | EMBO
Symposia 2019 : Funding of 60,000 Euros
The Wellcome Trust/DBT India Alliance
(India Alliance) and European Molecular
Biology Organization (EMBO) are looking
to fund interdisciplinary meetings that cov-
er the latest developments in research areas
underserved in India. These meetings should
address discovery and innovation through an
interdisciplinary approach, with the speakers
and participants discussing important global
challenges in the context of the life sciences.
Funding :
The maximum funding available for an In-
dia | EMBO Symposia is 60,000 Euros.
DST – Women
Scientists Scheme-C
(WOS-C) | Training W/
Stipend in Intellectual
Property Rights
Back To Lab –
Fellowship Programme
For Women
Researchers (Research
& Post-Doctoral)
EMBO Symposia 2019:
Funding of 60,000
Euros – Applications
Invited
candidates will undergo orientationprogram
on IPR at New Delhi for one month. After
orientation, candidates will be placed as In-
terns in and around the Coordination Centres
at Delhi, Pune, Chennai, and Kharagpur for
hands-on-training.
How to Apply:
Applications should be submitted through
online mode only.
Applications received in any other form
will not be considered. Link for online form
is available at www.pfc.org.in.
Whom to Contact:
For detailed information please contact
Mrs. Sangeeta Nagar, Scientist-E, TIFAC,
New Delhi-110016 [Email: kiranipr.pfc@ti-
fac.org.in, Phone: 011-42525802].
Last Date for Online Submissions: 19th
January, 2018
Implementing Agency:
Patent Facilitating Centre (PFC) Technolo-
gy Information Forecasting and Assessment
Council (TIFAC) [An autonomous body of
Department of Science & Technology (DST)]
1. Only women candidates are eligible to
apply.
2. Applicant should be of Kerala origin and
unemployed.
3. Age limit : 45 years
4. Applicant should have qualified
post-graduation with minimum 60% marks.
5. Applicant should have a valid Ph.D. reg-
istration in an institution of academic/ re-
search excellence in Kerala including R&D
institutions, University Departments, Govt.
Aided colleges, in any of the streams; Sci-
ence, Technology, Engineering, Agriculture
or Medicine (STEAM).
6. Applicant should have completed Ph.D.
course work.
7. Only those research scholars who are un-
der a career break during the course of their
Ph.D. programme due to maternity or other
valid reasons are eligible to apply.
8. Applicant should not have completed 4
years as on the date of Ph.D. registration.
9. Applicant should not be receiving any
fellowship or grant from any other source.
Research Fellowship :
The scheme offers monthly Research Fel-
lowship of Rs. 20,000/- + 10 % HRA in the
first two years and Rs. 25,000/- + 10 % HRA
in the third year, along with an annual contin-
gency grant of Rs. 20,000/-.
Features:
• The candidate should choose a Scientist
Mentor (preferably the Research guide)
who should be a permanent faculty of
the institution and should have atleast
5 years left in service in the Institute.
• The Scientist Mentor should constant-
ly monitor the progress of the project,
facilitate smooth implementation of the
programme and ensure timely submis-
sion of financial utilization certificates
by the institute to KSCSTE.
Duration
Normally for 3 years.
POST-DOCTORAL FELLOWSHIP
Objectives:
To provide Post-Doctoral Fellowship for
unemployed women researchers so as to fa-
cilitate their re-entry in Science research.
Who can apply?
Applicants should satisfy the following
conditions.
1. Only women candidates are eligible to
apply
2. Applicant should be of Kerala origin and
unemployed
3. Age limit: 50 years
4. Applicant should have qualified Ph.D. as
on the date of application and should have
scored minimum 60% marks for post-grad-
uation.
5. Applicant should have chosen an institu-
tion in Kerala belonging to the category of
R&D institutions(National/State level)/ Uni-
versity Departments.
6. Applicant should not be receiving any
fellowship or grant from any other source.
Research Fellowship :
The scheme offers Post-doctoral fellowship
of Rs.32,000/- + 10 % HRA p.m along with
an annual contingency grant of Rs. 50,000/-.
Features:
The candidate should choose a Scientist
Mentor who should be a permanent faculty
of the institution and should have at least 5
years left in service in the Institute.
The Scientist Mentor should constantly
monitor the progress of the project, facilitate
smooth implementation of the programme
and ensure timely submission of financial
utilization certificates by the institute to
KSCSTE.
Duration:
Normally for 3 years. However, on suc-
cessful completion of the project, in the case
of exceptionally meritorious post-doctoral
works, the work could be continued to a fur-
ther period of one to 1½ years with fellow-
ship support, subject to the recommendations
of the project review committee.
Address for Communication:
The Head
Women Scientists Division
Kerala State Council of Science, Technolo-
gy and Environment
Sasthra Bhavan, Pattom (P.O), Thiruva-
nanthapuram – 695 004
Ph: 0471 2548208, 2548346
e-mail: womenscientistkerala@gmail.com
10. Vol. 02 NO 1January 1st, 2018.
10
Eligibility:
India | EMBO Symposia must take place
in India, but scientists from anywhere in the
world are eligible to apply, independent of
their nationality.
India | EMBO Symposia must cover fron-
tier, pioneering and interdisciplinary areas
of life sciences that are underserved in In-
dia, and include speakers with interdiscipli-
nary expertise. Furthermore, the application
should include a list of (mostly) confirmed
speakers.
Applications must meet the following crite-
ria to be accepted:
• Applications must cover an area of re-
search that is underserved in India.
• Scientists from anywhere in the world are
eligible to apply, independent of their nation-
ality, but the meetings must be held in India.
• Meetings must be focused on frontier, pi-
oneering and interdisciplinary areas of life
sciences, and include speakers with interdis-
ciplinary expertise.
Please note: After the meeting, the organ-
izers must provide a position paper on the
theme that includes a plan to catalyze re-
search in that area in India. India Alliance
may consider funding research in that area
following expert advice and review.
Funding:
The maximum funding available for an In-
dia | EMBO Symposia is 60,000 euros.
Application process:
The deadline for applications for meetings
taking place between the 1st of January 2019
and the 31st of December 2019 is 15 Febru-
ary 2018, 14:00 CEST.
Applicants will be asked to complete an on-
line and an offline application form.
All incoming applications are screened to
ensure eligibility requirements are met.
The decision on which proposals receive
funding is jointly made by the EMBO Course
Committee and the India Alliance Meetings
Committee in May.
All applicants are informed of the outcome
of their application by email shortly after the
committee meetings.
For detailed information on the eligibility
criteria, application process, key dates, for-
mat of the meeting and required documenta-
tion, please consult the application guidelines
or visit India | EMBO Symposia website.
Contact:
Please do not contact the committee
members directly. This may lead to your
application being excluded from the re-
view process.
Please write to workshops@wellcomed-
bt.org for questions related to the propos-
al and courses_workshops@embo.org for
technical questions related to the applica-
tion system
11. Vol. 02 NO 1 January 1st, 2018.
11
ADMISSIONS
PhD Admissions
2018-2019 @
NII – National Institute
of Immunology
PhD Program 2018
Admissions @ DRILS –
Dr. Reddy’s Institute of
Life Sciences
National Institute of Immunology (NII)
invites applications for its Ph.D. pro-
gramme. Cutting-edge research at the
institute encompasses broad interdiscipli-
nary areas –
• Infection and Immunity;
• Genetics, Molecular, and Cellular Bi-
ology;
• Chamlcal, Structural, and Computa-
tional Biology; and
• Reproduction and Development
Minimum qualifications:
A. M.Sc. in any branch of Science (e.g.
Biology, Chemistry, Mathematics, Physics)
M.Tech., M.B.B.S., M.V.Sc.,M.Pharm. or
equivalent qualification as per the norms of
Jawaharlal Nehru University (JNU), New
Delhi
B. At. least 60% aggregate score or equiv-
alent grade in Senior Secondary Certificate
(10+2), Bachelor’s & Master’s degree is re-
quired. Due relaxations in aggregate score
will be applicable to SC/ST candidates.
Rounding off of percentage score to next in-
tegral value is not permitted.
C. Candidates appearing for the qualifying
examination this academic year are eligible
to apply; they will be admitted provisionally
pending satisfactory fulfilment of the above
requirements at the time of joining.
D. Reservations of seats: 15% for SC, 7.5%
for ST, 27% for OBC (non-creamy layer) and
3% for Physically Handicapped as per statu-
tory norms.
Selection procedure:
A. NII will select candidates for the Ph.D.
programme through the following CHAN-
NELS:
I. Entrance Exam to be conducted by NII at
five different centres – New Delhi, Hydera-
bad, Pune, Kolkata and Guwahati on Febru-
ary 18, 2018 (Sunday).
II. Joint Graduate Entrance Examination in
Biology and Interdisciplinary Life Sciences
(JGEEBI LS-2018) to be held on 10th De-
cember 2017). Candidates applying through
this channel must submit a separate appli-
cation to NII, New Delhi, along with appli-
cation fee, indicating their JGEEBILS hall
Ph.D. PROGRAM 2018
DR. REDDY’S INSTITUTE OF LIFE
SCIENCES
About DRILS:
The Dr. Reddy’s Institute of Life Sciences
was conceived in the context of globaliza-
tion, to foster research competence in India
and to bridge the divide between academic
research and the pharmaceutical & biotech-
nology industries..
The institute was incorporated as a non-prof-
it entity under Section 25 of the Indian com-
panies act, facilitating operational autonomy.
Construction of the DRILS building com-
prising 44 labs and an administrative block
and spanning ~130,000 sq.ft. in area, began
in 2004 and was completed in January 2007.
The institute was inaugurated as a pub-
lic-private partnership research institute on
29th January 2007, a culmination of the ef-
forts and initiative of the Andhra Pradesh
state government, Dr. Reddy’s laboratories
and the University of Hyderabad. The insti-
tute is located in the southeast corner of the
campus of the University, one of the largest
and greenest campuses in India.
Dr. Reddy’s Institute of Life Sciences
(DRILS) is a non-profit research institute
located on the campus of the University of
Hyderabad (www.drils.org).
DRILS announces admission to its 2018
Ph.D. program. Ph.D. Research will involve
specific topics in Chemistry or Biology (de-
tails can be found on our website).
Why DRILS?
• Outstanding research ambience.
• Student-centric faculty and teaching
philosophy.
• Faculty members from globally recog-
nized academic centers and industry.
• Research in frontier areas of Chemistry
and Biology, exposure to a crossdisci-
plinary
• environment.
• Focus on translational research and re-
search incubation.
• Located within a vibrant, world-class
academia-industry cluster.
ticket number.
B. The list of candidates shortlisted for in-
terviews shall be available on the website of
the institute as well as on the Notice Board of
the institute by March 30, 2018.
C. Interviews will be held at the National
Institute of Immunology, New Delhi from
13th to 15th June, 2018.
D. Candidates selected after the interviews
will be enrolled for the Ph.D. programme of
NII in academic affiliation with JNU, New
Delhi. Candidates joining the programme
will be paid second class train fare on provid-
ing the proof of journey.
Ph.D. Programme:
A. The programme will start on July 09,
2018 and the allotment of laboratories will
be made within two weeks based on the per-
formance of the candidate in the written test
and the interviews, and his/her choices of re-
search area.
B. The institute currently provides a Fel-
lowship of Rs 25000/- per month. Selected
candidates who are already fellowship awar-
dees from CSIR, UGC, ICMR, DBT or DST
will have to avail those fellowship only, as
per rules governed by the respective agency.
C. Shared hostel accommodation will be
available on request.
Application Procedure:
Online application fee of Rs 1000/- for
(GEN/OBC/PH) and Rs 500/- for SC/ST.
Candidates should submit their applications
online for admission through either of the
two CHANNELS using NII admission por-
tal. The details of the application process are
available at http://www.nii.res.in.
Applications should be submitted online
only (visit website http://www.nii.res.in.).
Online application facility will be available
at the NII website from 27th November to
10th January 2018 by 5.00 PM.
Applicants having difficulty in access-
ing NII Ph.D. admission portal may
contact the ‘ADMINISTRATIVE OF-
FICER, (Academic & Training) NATION-
AL INSTITUTE OF IMMUNOLOGY,
ARUNAASAF ALI MARG, and NEW
DELHl-110067’. Tel: 011-26717101, 011-
26703662 or 011-26703762.
Email: phdadm2017@nii.ac.in.
Name of the candidate and his/her date of
birth should match the corresponding entries
In the Secondary School Certificate or equiv-
alent.
Candidates must ensure that the information
furnished in the online application is true and
correct. If any discrepancy is observed at any
stage, NII reserves the right to cancel admis-
sion.
Application Deadline – 10th January
2018
Eligibility :
Post-Graduates with a valid fellowship
(CSIR, UGC, DBT, ICMR,
INSPIRE or other relevant ones).
How to apply?
Using our simple one-page online appli-
cation form:
https://tinyurl.com/drils-app
Read about our past students and more,
on our social media pages:
https://tinyurl.com/drils-fb
https://tinyurl.com/drils-linkedin
Application Deadline : Applications will
be accepted until January 30, 2018. Intake
will be based on position availability and
requirement.
Shortlisted candidates will undergo in-
terviews before final selection.
12. Vol. 02 NO 1January 1st, 2018.
12
www.biotecnika.org